Read the committee members' biographies and registered interests.
Professor Amanda Adler MD, PhD, FRCP
Professor of diabetic medicine and health policy, Oxford University
Amanda trained in economics, medicine and epidemiology with further training in pharmacovigilance and pharmacoepidemiology. She is professor of diabetic medicine and health policy at Oxford University. Other roles include consultant physician at Addenbrooke’s and Royal Papworth Hospitals in Cambridge, and member of an expert advisory group for the Commission on Human Medicines.
Amanda has advised the World Health Organization and supports projects that promote health technology assessment working with UK governmental agencies, NICE International, the International Decision Support Initiative (iDSI), the World Bank, and the Organisation for Economic Co-operation and Development (OECD).
Dr Sanjeev Patel BM DM FRCP
Consultant physician and senior lecturer in rheumatology
Sanjeev's clinical duties include acute intaking medicine and rheumatology services with a special interest in bone diseases. He is chair of the Medicines Management Committee of the Trust and chair of the Rheumatology Speciality Advisory Committee to the Royal College of Physicians.
Sanjeev's current research interests include the role of vitamin D in chronic diseases, and studies of secondary causes of osteoporosis and fractures, such as anorexia nervosa and chronic kidney disease.
Dr Carlo Berti
Consultant psychiatrist and honorary lecturer, Kent and Medway Partnership Trust
Biography to follow
Non-financial professional and personal interest
Ministry of Defence, novel psychoactive substnces expert, fee paying service.
Dr Laura Bojke
Reader in health economics, Centre for Health Economics, University of York
Laura has more than 20 years’ experience as a health economist. Over this time she has contributed to technology appraisals for NICE in her role as a member of one of the independent academic groups undertaking assessments and evidence reviews. She completed her PhD at the University of York in 2008, titled 'Characterising structural uncertainty within decision analytic models’. She has worked on a number of projects involving the use of expert elicited data within decision analytic models. Laura is particularly interested in this area and its application to issues of extrapolation uncertainty.
She has worked on a wide range of applied and methodological projects and has gained extensive experience of modelling the cost-effectiveness of arthritis and musculoskeletal diseases, especially psoriatic arthritis.
Laura currently co-leads the Applied Research and Collaborations (ARC) Yorkshire and Humber Health Economics theme. The program of work includes the use of economic evaluation across sectors, economic evaluation for local decision makers and the use of routine data for economic evaluation.
Policy manager within Health Research Authority
Maria is an NMC registered professional and a member of the Royal College of Nursing. She has extensive acute clinical and research work experience coordinating hyperacute investigational medicinal product/device/interventional trials.
This experience is well-complemented by:
- MSc in Clinical Drug Development providing thorough understanding of the drug development process.
- NIHR Advanced Leadership Programme enabling to explore management and leadership in health research on an individual, team, institution and system level.
- MSc in Psychology helping to negotiate problems and use de-escalation techniques when dealing with people.
Additional roles include:
- Alternate vice chair/expert member for Research Ethics Committee (HRA) (temporarily paused).
- Independent external NIHR research studies reviewer.
- NIHR Advanced Leadership Programme Community of Practice (COP) boundary spanning team lead/COP steering group member.
- Course mentor for Improving Healthcare Through Clinical Research Online Future Learn Courses, University of Leeds.
- Member of the NICE Adoption and Impact Reference Panel.
- COVID-19 vaccinator.
Denise has been working in the health tech industry for 23 years, mainly for Terumo Aortic, a manufacturer of surgical and endovascular devices for the treatment of aortic disease. I work closely with, and support clinicians in the Southeast.
Her clinical background is in critical care nursing within the NHS where she has helped to set up and run the first stand-alone high dependency unit.
Denise has always had a strong desire to help people where she can and has been a parent governor at school and currently volunteer for St John Ambulance on the COVID 19 national vaccination programme.
Professional and personal interests
Member of Association of British HealthTech Industries commercial committee and cardiovascualr committee
Husband also works for Terumo Aortic
Professor Iolo Doull
Iolo is a consultant respiratory paediatrician and honorary professor at the Children’s Hospital of Wales in Cardiff, and interim medical director of the Welsh Health Specialised Services Committee.
He is a former president of the British Paediatric Respiratory Society Health and previously served as the officer for Wales of the Royal College of Paediatrics and Child Health, and as president of the Welsh Paediatric Society. He was an expert advisor on our cystic fibrosis guideline and was previously and an expert advisor to the Commission on Human Medicines.
He has clinical and research interests in cystic fibrosis and respiratory diseases in children.
Dr James Fotheringham
James graduated from the University of Sheffield and following a PhD in performance measurement using routine healthcare data in renal services was funded by a National Institute of Health Research (NIHR) fellowship to improve outcomes for people on dialysis for kidney failure.
He works between the Sheffield Teaching Hospitals and University of Sheffield and a consultant in renal medicine since 2015, has published across a range of areas within kidney disease and co-authored guidelines. He has ongoing funded research by the NIHR evaluating the clinical and cost-effectiveness of kidney disease treatments.
Direct - financial
- Health gains from improved kidney graft survival – review of economic model.
- Charing a meeting for the British Transplant Society Industry symposium.
- Received speaker fees from Fresenius healthcare Germany.
Non-direct - financial
- Received fees for providing consultancy to Novartis for an Iscalimab randomized trial.
Dr Mark Glover
MRC clinician scientist, associate professor and honorary consultant physician, University of Nottingham
Mark trained in pre-clinical pharmacology and clinical medicine at Gonville and Caius College, Cambridge. He is a clinical pharmacologist and general physician at the University of Nottingham and Nottingham University Hospitals NHS Trust. His clinical and research interests are in hypertension.
Mark leads the hypertension service in Nottingham and leads an MRC funded research group focused on the molecular pathophysiology of sodium reabsorption in the distal nephron in Thiazide Induced Hyponatraemia and Gordon syndrome.
Mark is a member of the Prescribing Safety Assessment Board for UK medical students, and a member of the NICE hypertension in adults guideline committee.
Dr Nicholas Latimer
Reader in health economics, School of Health and Related Research, University of Sheffield
Nicholas is a health economist and a Yorkshire Cancer Research Senior Fellow. He studied economics at the University of Nottingham, health economics at the University of York, and has a PhD in health economics from the University of Sheffield.
Nicholas has worked as a health economist in academia and the pharmaceutical industry and has experience in the design and analysis of clinical trials and economic modelling. His main research interests are in survival analysis for economic evaluation, and the use of causal inference in health technology assessment.
Direct - financial
June 2017 to November 2017: BMS consultancy fee received on three occasions for attending advisory board meetings. June 2017 - nivolumab for metastatic microsatellite instability high colorectal cancer; November 2017 – nivolumab for first line non-small cell lung cancer and small cell lung cancer; November 2017 – nivolumab for adjuvant melanoma.
January 2017 to December 2017: Pfizer consultancy fees received. Member of Pfizer’s global modelling advisory committee. In 2017 discussed avelumab for ovarian, gastric, NSCLC and merkel cell carcinoma. In April 2017 provided advice to Pfizer on a statistical analysis plan relating to mylotarg for acute myeloid leukaemia.
May 2017: Merck consultancy fee received for providing a training course on treatment switching adjustment methods.
August 2017: fee received from a consultancy for work done on a Tesaro product. Reviewed survival analysis undertaken by FIECON on niraparib for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Note, contact and payment was solely with FIECON.
September 2017: Janssen consultancy fee received for providing a 0.5 day training course on survival analysis.
October 2017 to December 2017: Astra Zeneca consultancy fee received for giving advice on survival modelling for durvalumab as a monotherapy among patients with stage IIIB-IV NSCLC.
November 2017 to March 2018: Bluebirdbio consultancy fee received for attending an innovation panel meeting for the treatment of transfusion-dependent β-thalassemia (November 2017), and for attending an advisory board meeting on Lenti-D in Cerebral Adrenoleukodystrophy (March 2018).
May 2018: provided a training course to Pierre Fabre on treatment switching methods.
January 2019 to present: fee received from Pierre Fabre for advice on adjusting for treatment switching in the Beacon Study investigating Encorafenib + Cetuximab Plus or Minus Binimetinib in patients with BRAF V600E-mutant metastatic colorectal cancer.
May 2018 to present: provided modelling advice to Sirtex Medical UK for selective internal radiation therapy using microspheres (SIR-Spheres) for patients with locally advanced inoperable hepatocellular carcinoma.
November 2018 to March 2019: Bluebirdbio consultancy fee received for attending advisory board meetings on Lenti-globin for transfusion-dependent β-thalassemia and sickle cell disease and on Lenti-d for cerebral adrenoleukodystrophy.
January 2019: Sobi consultancy fee received for attending advisory board meeting on emapalumab for primary haemophagocytic lymphohistiocytosis.
March 2019: Atara Biotherapeutics consultancy fee received for attending advisory board meeting on tab-cel®, an allogeneic T-cell immunotherapy for patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disorder.
April 2019: Merck Sharp & Dohme Limited consultancy fee received for providing a one-day training course on survival analysis.
Direct - non-financial
September 2017 to November 2017: advised on modelling for enzalutamide in non-metastatic prostate cancer. Also gave advice to Astellas through the NICE Scientific Advice programme on enfortumab vedotin for urothelial carcinoma. No payment received.
January 2017 to present: data sharing agreements with the following companies, to aid my post-doctoral research fellowship:
- Roche - data from BRIM 3 trial (Vemurafenib for patients with unresectable stage IIIC or IV melanoma with V600 BRAF mutation) and data from the M77001 trial (trastuzumab for patients with HER2 positive metastatic breast cancer).
- Amgen - data from Study 20020408 (panitumumab for patients with metastatic colorectal cancer).
- Bohringher Ingelheim - data from LUX-Lung 1, LUX-Lung 3 and LUX-Lung 6. Afatinib for Stage IIIB/IV lung cancer.
No funding is involved in these agreements.
January 2017 to present: The University of Sheffield has received funding from BMS to conduct research into survival analysis methods, not product specific.
January 2017 to August 2017: The University of Sheffield received funding from Merck for analysing the pivotal trial of cladribine for Multiple Scelerosis. Work was completed in August 2017 although resulting papers are still being written.
Non-financial professional and personal
March 2019: currently on the project team for a project being carried out on the surrogate relationship between PFS and OS in cancer, funded by Takeda. The University of Sheffield receives the funding.
Dr Veline L'Esperance
NIHR doctoral research fellow/general practitioner, King's College London
Veline is an academic general practitioner in South London and an NIHR doctoral fellow at Kings College London. She holds a Master of Public Health and a Master of Science in Healthcare Policy and Management.
Her current research uses econometric methods to investigate the relationship between the allocation of resources and healthcare outcomes in general practice. Her ongoing interests are in primary care health economics and health service research.
She teaches on the Master of Public Health (MPH) programme at Kings College London. She was previously a National Medical Director's clinical fellow and prior to studying medicine she worked in the pharmaceutical industry.
Dr Rhiannon Owen
Associate professor in biostatistics at Swansea University
Rhiannon graduated with a BSc in Mathematics and Sports Science from Loughborough University. She completed an MSc in Medical Statistics from the University of Leicester, funded by the National Institute for Health Research (NIHR) Research Methods Fellowship. In 2013 she was awarded an NIHR Doctoral Research Fellowship to complete her PhD in biostatistics at the University of Leicester, titled ‘Bayesian methods in health technology assessment’.
Rhiannon is currently an associate professor in biostatistics at Swansea University Medical School. She has extensive experience of evidence synthesis methods for complex healthcare interventions and diagnostic tests. Rhiannon is a member of the Health Data Research (HDR) Community of Experts and associate member of the NICE Technology Support Unit.
Her main research interests include evidence synthesis methods for health technology assessment, network meta-analysis, Bayesian statistical methods in healthcare evaluation, analysis of large scale linked electronic health records, economic evaluation, and analysis of value of information. This work has been and is supported by HDR UK, the Medical Research Council, NIHR and the Academy of Medical Sciences.
From November 2019: paid consultant for Cogentia Healthcare Consulting Ltd and Daiichi Sankyo offering statistical advice and undertaking network meta-analysis of direct acting oral-anticoagulants for the prevention of stroke in atrial fibrillation.
September 2019 to January 2020: paid consultant for Cogentia Healthcare Consulting Ltd and Vifor Pharma offering statistical advice on evidence synthesis and undertaking network meta-analysis of iron therapy for iron deficiency without anaemia.
September 2019: paid tutor on the Indirect and Mixed Treatment Comparisons course at the University of Bristol.
May 2019 to June 2019: paid consultant and seminar speaker for F. Hoffmann-La Roche Ltd offering statistical advice on general methods in health technology assessment.
Ms Anna Pracz, MPharm PGDip
Senior medicines optimisation pharmacist, Greater Manchester Joint Commissioning Team
Anna is a senior medicines optimisation pharmacist at the Greater Manchester Joint Commissioning Team. She qualified from the Medical University of Warsaw and completed a postgraduate diploma (with merit) in clinical and health services pharmacy at the University of Manchester.
Anna has worked as a pharmacist across many settings including community, hospital, clinical trials and primary care. In her current role she supports the Greater Manchester Medicines Management Group and specialises in production of high quality evidence based guidance, particularly in the area of high cost medicines.
Anna has interest in managed entry of new medicines, guidance development processes and decision making.
Mr Peter Wheatley Price
Director of market access and pricing, Takeda UK
Peter qualified as a nurse in Oxford and after 7 years working in the NHS, joined the pharmaceutical industry. He has held a wide variety of commercial and management roles with responsibility at UK, EU and global levels. For the past 11 years he has worked developing strategies and appraisals for submission to NICE, the Scottish Medicines Consortium, the All Wales Medicines Strategy Group and other similar bodies globally to get access for patients.
Peter currently works for Takeda in the UK leading a team focussed on access for patients. He was a trustee for the National Ankylosing Spondylitis Society, a national patient charity for 12 years.
Health economist at the Manchester Centre for Health Economics, University of Manchester
Gabriel's research interests include decision-making when there are many potential options and/or separate, interacting decision-points. He is also interested in how to communicate the methods and results of health economic models.
Gabriel has contributed to NICE for many years. Before taking up his current job, he was lead health economist for about 30 NICE clinical guidelines. He also used to work for one of the independent academic groups that review evidence for technology appraisals.
Dr Stephen Smith, BSc MPhil MB BChir PhD MRCP
MRC post-doctoral clinical research fellow, University of Cambridge
Stephen is a clinical academic working at the University of Cambridge and EMBL-European Bioinformatics Institute. His clinical training is as a clinical pharmacologist and dermatologist at Addenbrookes in Cambridge.
Following a BSc in virology and PhD in Immuno-genomics from Edinburgh, he completed his medical degree in Cambridge, early clinical training at Addenbrookes and then MPhil from the Cambridge department of Applied Mathematics and Theoretical Physics. He went on to pursue an academic clinical career focused on applying bioinformatics to cancer biology.
Stephen has an ongoing interest in the application of computational modeling and machine learning techniques to healthcare datasets including to health economics and health technology.
Professor Toby Smith
Toby is an associate professor in physiotherapy at the University of East Anglia and senior trauma and orthopaedic physiotherapist at the Norfolk and Norwich University Hospital NHS Foundation Trust.
Toby’s clinical and research interests are predominantly based around the rehabilitation of people with lower limb (hip and knee) bone, joint and muscle diseases and following orthopaedic surgery
Mary has held several roles in her career as a clinical pharmacist and NHS manager, working as a commissioner head of medicines management, CSU head of secondary care services and individual funding requests, as an urgent care pharmacist, community pharmacist and senior clinical pharmacist manager in GP surgeries and primary care networks.
Mary was a clinical pharmacist ambassador for Health Education England (HEE), promoting clinical pharmacists in general practice and is also a NICE medicines and prescribing associate. She is an independent prescriber, with postgraduate qualifications in healthcare leadership and prescribing and therapeutics.
- Was a pharmacist ambassador for HEE East of England.
- Occasionally teaches GP trainees at University of East Anglia Norwich.
- Is an employee of Coastal Partnership GP practice and AGEM CSU.
Professor Nicky J Welton BSc MSc PhD
Professor of statistical and health economic modelling, University of Bristol
Nicky graduated with a BSc in mathematics from Sheffield University, an MSc in statistics from University College London, and a PhD in mathematical biology from the University of Bristol. She is currently professor of statistical and health economic modelling in the department of population health sciences at the University of Bristol. Here she leads the Multi-Parameter Evidence Synthesis research group and is director of the NICE Guidelines Technical Support Unit.
Her research interests include methods for evidence synthesis in health technology assessment, network meta-analysis, extrapolating survival curves, bias adjustment in evidence synthesis, use of evidence in economic models, and value of information analysis.
Direct - financial
June 2015 to present: contributes a session (for which she receives payment) on evidence synthesis for an Association of British Pharmaceutical Industry master class entitled: 'What makes a good submission to NICE'.
February 2019: received fees from the Association of the British Pharmaceutical Industry (ABPI) for delivering masterclasses on evidence synthesis.
Indirect - financial
January 2015 to September 2018: principle investigator for an MRS Methodology Research grant, in collaboration with Pfizer Ltd. Pfizer part fund a junior researcher on the project. The project is purely methodological and uses historical date on pain relief.
Principal Investigator for a research project part funded by the MRC and Pfizer Ltd. Pfizer part-funded a junior researcher until Dec 2018. The project is purely methodological, concerned with synthesis of dose-response and time-course information. The project used historical data on pain relief.
Mr Nigel Westwood
Nigel left school and joined the Royal Navy as an officer in 1975. After initial training he served on a number of ships including appointments as a bridge watch-keeping officer, gunnery officer, navigating officer, specialist warfare officer, second-in-command and as captain. On moving ashore he joined the staff of the Commander-in-Chief Fleet with responsibility for controlling naval operations around the world before moving to a new NATO headquarters where he worked on NATO policy and negotiating allocation of forces with nations.
After completing the prestigious Joint Service Defence College course he took up an appointment in the Ministry of Defence in London working on future equipment requirements.
In 1997 he showed the first signs of what subsequently proved to be ulcerative colitis and despite an intensive drug regime, his condition deteriorated forcing him to undergo a pan-proctocolectomy and obliging him to leave the Royal Navy in the rank of commander after 25 years service. He now owns and runs an information technology business.
He has been an active volunteer with a number of charities and organisations particularly Crohn's and Colitis UK since his diagnosis serving as a trustee and vice-chairman for a number of years before stepping back for personal reasons in 2010.
Professor Sarah Wild
Professor of epidemiology, University of Edinburgh
Sarah did her medical training in London and Cambridge. Her postgraduate experience included general medicine and diabetes, general practice and public health medicine, a cardiovascular epidemiology fellowship at Stanford University and a PhD at the London School of Hygiene and Tropical Medicine.
Sarah has worked at the University of Edinburgh since 2002 and is now professor of epidemiology and an honorary consultant in public health at Lothian NHS Board. Her main interests are the epidemiology and prevention of diabetes and other non-communicable diseases and the use of routine data for research.
Direct - non-financial
2016 to present: on the steering group of the Scottish Study Group for Diabetes in the Young whose meetings are supported by educational grants from Novo Nordisk.
Non-financial professional and personal interest
2016 to present: as a member of the steering group for the Scottish Study Group for Care of Diabetes in the Young Sarah receives subsidised accommodation, subsistence and conference attendance for the bi-annual meetings of the group because the meeting is supported financially by Novo Nordisk.
Dr Stuart Williams
Consultant radiologist, Norfolk and Norwich University Hospital
Stuart qualified in medicine from Oxford University and worked in a variety of medical jobs in Oxford, Birmingham and London before returning to Oxford to train in radiology. Since 2001 he has been a consultant radiologist at Norwich and honorary senior lecturer at Norwich Medical School. He has variously been head of training, radiology clinical director, RCR regional chair and Trust lead for audit and improvement.
Between 2010 and 2013, Stuart was one of the first cohort of NICE clinical fellows and was subsequently a member of the guideline development group around recognition and referral of suspected cancer (NG12).
Mr Tony Wootton
Tony is a retired secondary school headteacher. After graduating from Newcastle University he started his working life as an accountant before embarking on a teaching career which spanned nearly 30 years, working in Leeds, London and North Yorkshire.
Since retiring Tony has served on a number of NICE guideline development groups covering topics ranging from ‘anti-social behaviour and conduct disorders’ through to ‘achieving better access to urgent and emergency mental health care for children and young people’ and most recently ‘Suspected Neurological Conditions Recognition and Referral’.
Tony has been a member of the Lymphoma Association for a number of years since his own diagnosis of Non-Hodgkin Lymphoma in 2009. In recent years Tony and his wife have provided short break respite care to children and young people with learning difficulties.